D.E. Shaw & Co
ORKA

D.E. Shaw & Co’s Oruka Therapeutics ORKA Stock Holding History

D.E. Shaw & Co’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-76,415
Closed -$2.32M – 5164
2025
Q4 		$2.32M Sell
76,415
-19,002
-20% -$529K ﹤0.01% 2934
2025
Q3 		$1.83M Buy
95,417
+27,772
+41% +$412K ﹤0.01% 3043
2025
Q2 		$758K Buy
+67,645
New +$705K ﹤0.01% 3420

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

D.E. Shaw & Co's ORKA Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 76,415 shares — an estimated $2.32M sold.

D.E. Shaw & Co first reported a position in ORKA in Q2 2025 and held it in 3 quarters. The position peaked at $2.32M in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 76,415 Oruka Therapeutics shares in Q1 2026, an estimated $2.32M.
  • D.E. Shaw & Co first reported a position in Oruka Therapeutics in Q2 2025 and held it in 3 quarters.
  • D.E. Shaw & Co's Oruka Therapeutics position peaked at $2.32M in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.